Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial
Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial
Background: there is evidence that commercially available behavioural weight management programmes can lead to short-term weight loss and reductions in glycaemia. Here, we aimed to provide the 5-year impact and cost-effectiveness of these interventions compared with a brief intervention.
Methods: WRAP was a non-blinded, parallel-group randomised controlled trial (RCT). We recruited from primary care practices in England and randomly assigned participants to one of three interventions (brief intervention, 12-week open-group behavioural programme [WW, formerly Weight Watchers], or a 52-week open-group WW behavioural programme) in an uneven (2:5:5) allocation. Participants were followed up 5 years after randomisation using data from measurement visits at primary care practices or a research centre, review of primary care electronic medical notes, and self-report questionnaires. The primary outcome was change in weight at 5 years follow-up, assessed using analysis of covariance. We also estimated cost-effectiveness of the intervention. This study is registered at Current Controlled Trials, ISRCTN64986150.
Findings: between Oct 18, 2012, and Feb 10, 2014, we recruited 1269 eligible participants (two participants were randomly assigned but not eligible and therefore excluded) and 1040 (82%) consented to be approached about additional follow-up and to have their medical notes reviewed at 5 years. The primary outcome (weight) was ascertained for 871 (69%) of 1267 eligible participants. Mean duration of follow-up was 5·1 (SD 0·3) years. Mean weight change from baseline to 5 years was −0·46 (SD 8·31) kg in the brief intervention group, −1·95 (9·55) kg in the 12-week programme group, and −2·67 (9·81) kg in the 52-week programme. The adjusted difference in weight change was –1·76 (95% CI –3·68 to 0·17) kg between the 52-week programme and the brief intervention; –0·80 (–2·13 to 0·54) kg between the 52-week and the 12-week programme; and –0·96 (–2·90 to 0·97) kg between the 12-week programme and the brief intervention. During the trial, the 12-week programme incurred the lowest cost and produced the highest quality-adjusted life-years (QALY). Simulations beyond 5 years suggested that the 52-week programme would deliver the highest QALYs at the lowest cost and would be the most cost-effective. No participants reported adverse events related to the intervention.
Interpretation: although the difference in weight change between groups was not statistically significant, some weight loss was maintained at 5 years after an open-group behavioural weight management programme. Health economic modelling suggests that this could have important implications to reduce the incidence of weight-related disease and these interventions might be cost-saving.
Funding: the UK National Institute for Health and Care Research Programme Grants for Applied Research and the Medical Research Council.
e866-e875
Ahern, Amy L.
92728e64-2b90-4ffc-8198-cbeb85641afc
Breeze, Penny
682ffcb7-4ecc-4659-a081-42a255060bf9
Fusco, Francesco
9e00d498-5d71-4c89-a0e0-a6357c9121b9
Sharp, Stephen J
65e1326f-97f8-4654-b75c-15d046f00532
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Wheeler, Graham M.
a45dc7be-5fd7-4982-adbb-b855eb3a157f
Hill, Andrew J.
7c2c6b8e-3649-4a70-aac6-0acc9f89a99a
Hughes, Carly A.
7b4ac4c0-6088-4c56-ba6a-e09aff9f2709
Duschinsky, Robbie
3181c391-bf1d-4d34-9dc4-038be08d049c
Thomas, Chloe
2af463a8-c25a-4660-bb21-c2b70f57d25c
Bates, Sarah
186dd4c9-483d-4770-b818-c4e5aa334898
Woolston, Jenny
09d52e82-5770-460d-b402-210885a32374
Stubbings, Marie
ffcf2bad-e3ee-492b-9971-775392c8aefd
Whittle, Fiona
3a26fdeb-412a-4c8f-8569-8b47b5033d4d
Boothby, Clare
e5b82384-75cc-4982-b83e-856762f79858
Bostock, Jennifer
209fe50a-0710-4023-aa51-5582b8b0eca5
Jebb, Susan
476244f5-fa7e-4e04-bbc1-d9c0d321f286
Aveyard, Paul
cb22de2b-29bc-4886-8a00-6e68aea59509
Boyland, Emma
5446e9c3-b05d-4145-b0ea-3c937e0cb96b
Halford, Jason C.G.
cd338570-b681-4100-9c43-a2540f0ffa6b
Morris, Stephen
0abf603b-3b19-43a9-be25-a0f1e76c574c
Brennan, Alan
5172d81f-9709-449f-850f-512ffe4cb21d
Griffin, Simon J.
f12ee1b9-fef5-46ab-b5a4-50b66e6c93c8
October 2022
Ahern, Amy L.
92728e64-2b90-4ffc-8198-cbeb85641afc
Breeze, Penny
682ffcb7-4ecc-4659-a081-42a255060bf9
Fusco, Francesco
9e00d498-5d71-4c89-a0e0-a6357c9121b9
Sharp, Stephen J
65e1326f-97f8-4654-b75c-15d046f00532
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Wheeler, Graham M.
a45dc7be-5fd7-4982-adbb-b855eb3a157f
Hill, Andrew J.
7c2c6b8e-3649-4a70-aac6-0acc9f89a99a
Hughes, Carly A.
7b4ac4c0-6088-4c56-ba6a-e09aff9f2709
Duschinsky, Robbie
3181c391-bf1d-4d34-9dc4-038be08d049c
Thomas, Chloe
2af463a8-c25a-4660-bb21-c2b70f57d25c
Bates, Sarah
186dd4c9-483d-4770-b818-c4e5aa334898
Woolston, Jenny
09d52e82-5770-460d-b402-210885a32374
Stubbings, Marie
ffcf2bad-e3ee-492b-9971-775392c8aefd
Whittle, Fiona
3a26fdeb-412a-4c8f-8569-8b47b5033d4d
Boothby, Clare
e5b82384-75cc-4982-b83e-856762f79858
Bostock, Jennifer
209fe50a-0710-4023-aa51-5582b8b0eca5
Jebb, Susan
476244f5-fa7e-4e04-bbc1-d9c0d321f286
Aveyard, Paul
cb22de2b-29bc-4886-8a00-6e68aea59509
Boyland, Emma
5446e9c3-b05d-4145-b0ea-3c937e0cb96b
Halford, Jason C.G.
cd338570-b681-4100-9c43-a2540f0ffa6b
Morris, Stephen
0abf603b-3b19-43a9-be25-a0f1e76c574c
Brennan, Alan
5172d81f-9709-449f-850f-512ffe4cb21d
Griffin, Simon J.
f12ee1b9-fef5-46ab-b5a4-50b66e6c93c8
Ahern, Amy L., Breeze, Penny, Fusco, Francesco, Sharp, Stephen J, Islam, Nazrul, Wheeler, Graham M., Hill, Andrew J., Hughes, Carly A., Duschinsky, Robbie, Thomas, Chloe, Bates, Sarah, Woolston, Jenny, Stubbings, Marie, Whittle, Fiona, Boothby, Clare, Bostock, Jennifer, Jebb, Susan, Aveyard, Paul, Boyland, Emma, Halford, Jason C.G., Morris, Stephen, Brennan, Alan and Griffin, Simon J.
(2022)
Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial.
The Lancet Public Health, 7 (10), .
(doi:10.1016/S2468-2667(22)00226-2).
Abstract
Background: there is evidence that commercially available behavioural weight management programmes can lead to short-term weight loss and reductions in glycaemia. Here, we aimed to provide the 5-year impact and cost-effectiveness of these interventions compared with a brief intervention.
Methods: WRAP was a non-blinded, parallel-group randomised controlled trial (RCT). We recruited from primary care practices in England and randomly assigned participants to one of three interventions (brief intervention, 12-week open-group behavioural programme [WW, formerly Weight Watchers], or a 52-week open-group WW behavioural programme) in an uneven (2:5:5) allocation. Participants were followed up 5 years after randomisation using data from measurement visits at primary care practices or a research centre, review of primary care electronic medical notes, and self-report questionnaires. The primary outcome was change in weight at 5 years follow-up, assessed using analysis of covariance. We also estimated cost-effectiveness of the intervention. This study is registered at Current Controlled Trials, ISRCTN64986150.
Findings: between Oct 18, 2012, and Feb 10, 2014, we recruited 1269 eligible participants (two participants were randomly assigned but not eligible and therefore excluded) and 1040 (82%) consented to be approached about additional follow-up and to have their medical notes reviewed at 5 years. The primary outcome (weight) was ascertained for 871 (69%) of 1267 eligible participants. Mean duration of follow-up was 5·1 (SD 0·3) years. Mean weight change from baseline to 5 years was −0·46 (SD 8·31) kg in the brief intervention group, −1·95 (9·55) kg in the 12-week programme group, and −2·67 (9·81) kg in the 52-week programme. The adjusted difference in weight change was –1·76 (95% CI –3·68 to 0·17) kg between the 52-week programme and the brief intervention; –0·80 (–2·13 to 0·54) kg between the 52-week and the 12-week programme; and –0·96 (–2·90 to 0·97) kg between the 12-week programme and the brief intervention. During the trial, the 12-week programme incurred the lowest cost and produced the highest quality-adjusted life-years (QALY). Simulations beyond 5 years suggested that the 52-week programme would deliver the highest QALYs at the lowest cost and would be the most cost-effective. No participants reported adverse events related to the intervention.
Interpretation: although the difference in weight change between groups was not statistically significant, some weight loss was maintained at 5 years after an open-group behavioural weight management programme. Health economic modelling suggests that this could have important implications to reduce the incidence of weight-related disease and these interventions might be cost-saving.
Funding: the UK National Institute for Health and Care Research Programme Grants for Applied Research and the Medical Research Council.
Text
PIIS2468266722002262
- Version of Record
More information
e-pub ahead of print date: 29 September 2022
Published date: October 2022
Additional Information:
Funding Information:
We thank the research and Clinical Research Network staff who supported data collection and thank all staff from the MRC Epidemiology Unit Functional Group Teams. We are grateful to the UK National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre Core Biochemical Assay Laboratory at Addenbrookes Hospital for analysing the blood samples. We also thank the WRAP study participants, and the ongoing support of our Patient Public Involvement Panel. The 5-year follow-up of the WRAP trial was funded by the UK NIHR under its Programme Grants for Applied Research Programme (RP-PG-0216–20010). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The WRAP trial was funded by the National Prevention Research Initiative through the UK Medical Research Council (MRC; MR/J000493). WW (formerly Weight Watchers) provided the intervention at no cost via an MRC Industrial Collaboration Award. ALA, SJG, and SJS are supported by the MRC (MC_UU_00006/6). The University of Cambridge has received salary support in respect of SJG from the National Health Service in the East of England through the Clinical Academic Reserve. PA and SAJ were funded by the NIHR Oxford Biomedical Research Centre and NIHR Oxford and Thames Valley Applied Research Collaboration. PA is an NIHR senior investigator.
Funding Information:
We thank the research and Clinical Research Network staff who supported data collection and thank all staff from the MRC Epidemiology Unit Functional Group Teams. We are grateful to the UK National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre Core Biochemical Assay Laboratory at Addenbrookes Hospital for analysing the blood samples. We also thank the WRAP study participants, and the ongoing support of our Patient Public Involvement Panel. The 5-year follow-up of the WRAP trial was funded by the UK NIHR under its Programme Grants for Applied Research Programme (RP-PG-0216–20010). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The WRAP trial was funded by the National Prevention Research Initiative through the UK Medical Research Council (MRC; MR/J000493). WW (formerly Weight Watchers) provided the intervention at no cost via an MRC Industrial Collaboration Award. ALA, SJG, and SJS are supported by the MRC (MC_UU_00006/6). The University of Cambridge has received salary support in respect of SJG from the National Health Service in the East of England through the Clinical Academic Reserve. PA and SAJ were funded by the NIHR Oxford Biomedical Research Centre and NIHR Oxford and Thames Valley Applied Research Collaboration. PA is an NIHR senior investigator.
Funding Information:
ALA reports research grants from the UK National Institute for Health and Care Research (NIHR), UK Medical Research Council (MRC) and the European Association for the Study of Obesity and membership of the Scientific Advisory Board for WW (all payments to her institution). PB reports research grants to her institution from NIHR and consultancy fees from Genomics. NI reports grants from the UK Office for National Statistics, Canadian Institutes of Health Research, Health Data Research UK, and NIHR; is an advisory board member of the WHO-UN Technical Advisory Board, The BMJ Research Forum and BMJ Medicine; and has received consultancy fees and payments from The BMJ. GMW reports grants from MRC and Innovate UK; has received payment from AstraZeneca and support for meeting attendance from Eli Lilly; and is a committee member of the NIHR Statistics Group Early Stage Trials Section, UK National Cancer Research Institute Teenage and Young Adult and Germ Cell Therapies subgroup, and the MRC Experimental Medicine Funding Panel. AJH reports grants to his institution from NIHR and payment for advice from Slimming World. CAH reports consultancy fees from Novo Nordisk; payments or honoraria for presentations; manuscript writing or educational events from Novo Nordisk, Ethicon, Alva Health and International Medical Press; and is an Advisory Board Member for Novo Nordisk. RD reports research grants from NIHR and the Wellcome Trust. SB reports research grants from the Wellcome Trust and NIHR; consultancy fees from the UK Office for Health Improvement and Disparities and Dark Peak Analytics; and is on the Editorial Board of the Journal of Medical Decision Making. SJ has received grants from NIHR and is Chair of the UK Food Standards Agency. PA reports research grants to his institution from NIHR, British Heart Foundation and Nestle Life Sciences, and materials or services from Nestle Life Sciences. EB reports grants to her institution from NIHR, Public Health England, and WHO, and consultancy fees from WHO. JCGH has received grants from Novo Nordisk and the American Beverage Association; consulting fees from Novo Nordisk, Dupont, Boheim Inhelheim, and Mars; support for meeting attendance from Novo Nordisk; and is an Advisory Board Member for Dupont (all payments to his institution). SM and AB report grant funding to their institution from NIHR. SJG reports grants to his institution from NIHR and MRC; consultancy fees to his institution from Genomics; payments for educational events from AstraZeneca; and unpaid membership of the Board of Trustees for the Novo Nordisk UK Research Foundation. FF, SJS CC, CT, JW, MS, FW, and CB report no competing interests beyond funding to their institutions for the current project.
Publisher Copyright:
© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
Identifiers
Local EPrints ID: 471104
URI: http://eprints.soton.ac.uk/id/eprint/471104
ISSN: 2468-2667
PURE UUID: a8a41982-e9ba-4e93-af44-aff56a3d0244
Catalogue record
Date deposited: 26 Oct 2022 16:45
Last modified: 17 Mar 2024 04:15
Export record
Altmetrics
Contributors
Author:
Amy L. Ahern
Author:
Penny Breeze
Author:
Francesco Fusco
Author:
Stephen J Sharp
Author:
Nazrul Islam
Author:
Graham M. Wheeler
Author:
Andrew J. Hill
Author:
Carly A. Hughes
Author:
Robbie Duschinsky
Author:
Chloe Thomas
Author:
Sarah Bates
Author:
Jenny Woolston
Author:
Marie Stubbings
Author:
Fiona Whittle
Author:
Clare Boothby
Author:
Jennifer Bostock
Author:
Susan Jebb
Author:
Paul Aveyard
Author:
Emma Boyland
Author:
Jason C.G. Halford
Author:
Stephen Morris
Author:
Alan Brennan
Author:
Simon J. Griffin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics